A Study to Evaluate INCB161734 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation
Recruiting now Phase 1 NCT06179160
Run by Incyte Corporation · for 18 and older · All sexes
What this study is about
This study is conducted to determine the safety and tolerability of INCB161734 as a single agent or in combination with other anticancer therapies.
Who can join (things the study team will check)
✅ You may be able to join if…
- ≥18 years old.
- Locally advanced or metastatic solid tumor with KRAS G12D mutation.
- For Part 1a and Part 2 Combination Groups 1, 2, and 7: Disease progression on prior standard treatment, intolerance to or ineligibility for standard treatment, declined available therapies that are known to confer clinical benefit, or no standard available treatment to improve the disease outcome.
- Cohort specific requirements aas defined in the protocol.
- Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
🚫 You may not be able to join if…
- Prior treatment with any KRAS G12D inhibitor
- Known additional invasive malignancy within 1 year of the first dose of study drug
- History of organ transplant, including allogeneic stem cell transplantation
- Significant, uncontrolled medical condition
- History or presence of an ECG abnormality
- Inadequate organ function Other protocol-defined Inclusion/Exclusion Criteria may apply
Where this trial is running
- Mayo Clinic Hospital, Phoenix, Arizona, United States
- Stanford University, Palo Alto, California, United States
- UCLA Healthcare Hematology-Oncology, Santa Monica, California, United States
- Sarah Cannon Research Institue At Healthone, Denver, Colorado, United States
- Mayo Clinic Florida, Jacksonville, Florida, United States
- Florida Cancer Specialists, Sarasota, Florida, United States
- Florida Cancer Specialists, Sarasota, Florida, United States
- Sidney Kimmel Comprehensive Cancer Center At Johns Hopkins, Baltimore, Maryland, United States
- Dana Farber Cancer Institute, Boston, Massachusetts, United States
- Mayo Clinic, Rochester, Minnesota, United States
- Hackensack University Medical Center, Hackensack, New Jersey, United States
- Weill Cornell Medicine, New York, New York, United States
+ 25 more sites.
Who to contact
Incyte Corporation Call Center (US) · 1.855.463.3463 · medinfo@incyte.com
It's completely normal to call and ask questions before deciding anything. Mention the study ID: NCT06179160.
Verify everything on the official ClinicalTrials.gov record. Page updated July 2026.
Beacon is an information tool, not medical advice. Whether a trial is right for you is a decision for you, your doctor, and the study team. Trial details come from the official registry, ClinicalTrials.gov, and may change — always confirm with the study team. Beacon collects no data about you: this page has no cookies, no accounts, and no tracking.